For primary cells, transient transfection is an inefficient method of siRNA delivery. Electroporation of primary T cells results in successful gene silencing only if very high siRNA doses are used ...

Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell Carcinoma Marlborough, ...

RNA interference is a conserved biological response to double-stranded RNA that regulates gene expression ... Ago proteins constitute a key component of the RNA-induced silencing complex (RISC), ...

The aggregate gross proceeds to the Company from the offering are expected to be $1.83 million, before deducting the placement agent fees and other offering expenses payable by the Company. The ...

Benitec has a market cap of $250mn, $67.8mn in cash, and a cash runway of over 10 quarters, but faces risks due to its small ...

Shares of Phio Pharmaceuticals Corp. soared 291% Jan. 13 on news that two patients with cutaneous squamous cell carcinoma had a complete response following treatment with the company’s Intasyl siRNA ...

The US biotech has just reported phase 2 trial results with the small, interfering RNA (siRNA) gene-silencing drug showing that it an cause a 90% or greater reduction in Lp(a) levels – a risk ...

Detailed price information for Phio Pharmaceuticals Corp (PHIO-Q) from The Globe and Mail including charting and trades.

Detailed price information for Phio Pharmaceuticals Corp (PHIO-Q) from The Globe and Mail including charting and trades.

(NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the body's immune cells more effective in killing ...